BeiGene Newsroom

BeiGene Analyst Ratings

BenzingaAug 20 10:14 ET

J.P. Morgan Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $200

Moomoo NewsAug 20 08:33 ET

TD Cowen Initiates BeiGene(BGNE.US) With Buy Rating, Announces Target Price $254

Moomoo NewsAug 19 07:32 ET

TD Cowen Sticks to Its Buy Rating for BeiGene (BGNE)

TipRanksAug 19 07:01 ET

Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $284

Moomoo NewsAug 16 09:32 ET

Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $284

Moomoo NewsAug 16 08:32 ET

Jefferies Sticks to Their Buy Rating for BeiGene (BGNE)

TipRanksAug 16 08:07 ET

BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $198

Moomoo NewsAug 13 10:32 ET

Hold Rating on BeiGene Amid Mixed Drug Performance and Strong Pipeline Potential

TipRanksAug 13 10:21 ET

BeiGene's Strong Financial and Clinical Prospects Solidify Buy Rating

TipRanksAug 9 12:27 ET

BeiGene Analyst Ratings

BenzingaAug 8 15:14 ET

BeiGene's Brukinsa Drives Strong Growth and Justifies Buy Rating

TipRanksAug 8 07:28 ET

Buy Rating for BeiGene Backed by Brukinsa's Market Growth and Strong Financial Outlook

TipRanksAug 7 15:22 ET

Nomura Adjusts BeiGene's Price Target to HK$158.37 From HK$150, Keeps at Buy

MT NewswiresJul 16 03:26 ET

B of A Securities Maintains Neutral on BeiGene, Lowers Price Target to $152.5

BenzingaJul 9 13:22 ET

BeiGene Analyst Ratings

BenzingaJul 9 13:21 ET

BeiGene Analysis: Hold Rating Amidst Mixed Drug Sales Performance and Market Competition

TipRanksJul 9 06:37 ET

BeiGene Performance Analysis: A Hold Rating With Cautious Optimism Amidst Competitive Pressures

TipRanksMay 15 05:52 ET

BeiGene's Soaring Sales and Path to Profitability Reinforce Buy Rating

TipRanksMay 10 02:16 ET

Buy Rating Affirmed for BeiGene on Strong Q4 Performance and Promising Brukinsa Sales

TipRanksMay 10 01:30 ET